News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Giuseppe Curigliano: Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer
Photo taken from Giuseppe Curigliano/LinkedIn
Jan 31, 2025, 07:23

Giuseppe Curigliano: Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief, shared on X:

“Adding nivolumab to neoadjuvant chemotherapy significantly increased pCR rates in high-risk, early-stage ER+/HER2− BC, particularly in patients with higher stromal tumor-infiltrating lymphocyte levels or programmed death ligand 1 expression.”

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial | Nature Medicine

Authors: Sherene Loi, Roberto Salgado, Giuseppe Curigliano, Roberto Iván Romero Díaz, Suzette Delaloge, Carlos Ignacio Rojas García, Marleen Kok, Cristina Saura, Nadia Harbeck, Elizabeth A. Mittendorf, Denise A. Yardley, Alberto Suárez Zaizar, Facundo Rufino Caminos, Andrei Ungureanu, Joaquin G. Reinoso-Toledo, Valentina Guarneri, Daniel Egle, Felipe Ades, Misena Pacius, Aparna Chhibber, Rajalakshmi Chandra, Raheel Nathani, Thomas Spires, Jenny Qun Wu, Lajos Pusztai, Heather McArthur

Giuseppe Curigliano: Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer

Alberto Suárez Zaizar Andrei Ungureanu Aparna Chhibber cancer Carlos Ignacio Rojas García Cristina Saura Daniel Egle Denise A. Yardley Elizabeth A. Mittendorf Facundo Rufino Caminos Felipe Ades Giuseppe Curigliano Heather McArthur Jenny Qun Wu Joaquin G. Reinoso-Toledo Lajos Pusztai Marleen Kok Misena Pacius Nadia Harbeck OncoDaily Oncology Raheel Nathani Rajalakshmi Chandra Roberto Iván Romero Díaz Roberto Salgado Sherene Loi Suzette Delaloge Thomas Spires Valentina Guarneri
Special Coverage
Insight
Jan 31, 2025, 08:42
Commemorating the 1-year anniversary of the partnership with Siemens Healthineers - City Cancer Challenge
Blog
Jan 31, 2025, 08:38
Meet the speakers of the 9th Annual Conference of ELLOK - Zenia Saridaki
Blog
Jan 31, 2025, 07:57
Applications are still open for the M2ICOS project - European School of Oncology
Blog
Jan 31, 2025, 07:35
Dasatinib could be repurposed to treat pediatric ependymoma - NFCR
Blog
Jan 31, 2025, 07:32
SIOG - Can Remote Patient Monitoring improve Cancer Care for older adults?
Blog
Jan 31, 2025, 07:27
Paolo Tarantino: Outcomes and Treatment Patterns for Stage I HER2-Positive Breast Cancer
Blog
Jan 31, 2025, 07:23
Giuseppe Curigliano: Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer
Blog
Jan 31, 2025, 07:21
Shahrin Ahmed: The key solutions for increasing life-saving cervical cancer screenings
Blog
Jan 31, 2025, 07:20
Elvina Almuradova: Pertuzumab + trastuzumab retreatment to prolong OS in HER2+ metastatic breast cancer
Blog
Jan 31, 2025, 07:17
Catherine Alix-Panabières: Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer
Blog
Jan 31, 2025, 07:14
Emily Drake: Thrilled to be in Toronto at The Hospital for Sick Children for the ACCESS annual meeting
Blog
Jan 31, 2025, 07:12
Julie S. Torode: Celebrating the Winners of the APCA\TCT 2024 Photography Competition